Mechanisms of platelet-activating factor-induced enhancement of VEGF expression

Cellular Physiology and Biochemistry

Volumn 27, Issue 1, 2011, Pages 55-62

  Kim, Han A ^a   Seo, Kook Heon ^a   Kang, Yeong Rim ^a   Ko, Hyun Mi ^a   Kim, Kyoung Jin ^a   Back, Hae Kyong ^a   Lee, Hern Ku ^b   Im, Suhn Young ^a  

^a Chonnam National University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

Egr 1; NF B; p53; PAF; Sp 1; VEGF

Indexed keywords

BEPAFANT; EARLY GROWTH RESPONSE FACTOR 1; LUCIFERASE; MESSENGER RNA; PROTEIN P53; THROMBOCYTE ACTIVATING FACTOR; VASCULOTROPIN;

ARTICLE; ASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; DATA ANALYSIS; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; MEDICAL RECORD; MUTANT; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 79951624379     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000325205     Document Type: Article

References (46)

1. Fukuda AI, Breuel KF: Effect of platelet activating factor on embryonic development and implantation in the mouse. Hum Reprod 1996;11:2746-2749. (Pubitemid 27060750)
2. Nilsson G, Metcalfe DD, Taub DD: Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response. Immunology 2000;99:314-319. (Pubitemid 30093679)
3. Braquet P, Paubert-Braquet M, Bourgain RH, Bussolino F, Hosford D: PAF/ cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. J Lipid Mediat 1989;1:75-112. (Pubitemid 19132700)
4. Kasperska-Zajac A, Brzoza Z, Rogala B: Platelet activating factor as a mediator and therapeutic approach in bronchial asthma. Inflammation 2008;31:112-120.
5. Kopp EB, Ghosh S: NF-kappa B and rel proteins in innate immunity. Adv Immunol 1995;58:1-27.
6. Im SY, Han SJ, Ko HM, Choi JH, Chun SB, Lee DG, Ha TY, Lee HK: Involvement of nuclear factor-kappa B in platelet-activating factor-mediated tumor necrosis factor-alpha expression. Eur J Immunol 1997;27:2800-2804. (Pubitemid 27478346)
7. Han SJ, Ko HM, Choi JH, Seo KH, Lee HS, Choi EK, Choi IW, Lee HK, Im SY: Molecular mechanisms for lipopolysac-charide-induced biphasic activation of nuclear factor-kappa B (NF-kappa B). J Biol Chem 2002;277:44715-44721. (Pubitemid 36159062)
8. Choi JH, Ko HM, Kim JW, Lee HK, Han SS, Chun SB, Im SY: Platelet-activating factor-induced early activation of NF-kappa B plays a crucial role for organ clearance of Candida albicans. J Immunol 2001;166:5139-5144.
9. Ko HM, Seo KH, Han SJ, Ahn KY, Choi IH, Koh GY, Lee HK, Ra MS, Im SY: Nuclear factor kappaB dependency of platelet-activating factor-induced angio-genesis. Cancer Res 2002;62:1809-1814. (Pubitemid 34408507)
10. Seo KH, Lee HS, Jung B, Ko HM, Choi JH, Park SJ, Choi IH, Lee HK, Im SY: Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Res 2004;64:6482-6488. (Pubitemid 39297904)
11. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothe-lial growth factor is a secreted angiogenic mitogen. Science 1989;264:1306-1309. (Pubitemid 20066716)
12. Ko HM, Jung HH, Seo KH, Kang YR, Kim HA, Park SJ, Lee HK, Im SY: Platelet-activating factor-induced NF-kappaB activation enhances VEGF expression through a decrease in p53 activity. FEBS Lett 2006;580:3006-3012. (Pubitemid 43729668)
13. Ravi R, Mookerjee B, Van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ, Bedi A: p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 1998;58:4531-4536. (Pubitemid 28480608)
14. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, Wajant H: p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001;20:571-580. (Pubitemid 32156181)
15. Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady JN: Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol Cell Biol 2000;20:3377-3386. (Pubitemid 30243883)
16. Dey A, Tergaonkar V, Lane DP: Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008;7:1031-1040.
17. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R: p53 and vas-cular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000;89:51-62. (Pubitemid 30078750)
18. Pal S, Datta K, Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001;61:6952-6957. (Pubitemid 32896524)
19. Forsythe JA, Jiang BH, Iyer N V, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cello Biol 1996;16:4604-4613. (Pubitemid 26272112)
20. Mechtcheriakova D, Wlachos A, Holzmüller H, Binder BR, Hofer E: Vascular endothelial cell growth factor-induced tissue factor expression in endothe-lial cells is mediated by EGR-1. Blood 1999;93:3811-3823. (Pubitemid 29249828)
21. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular en-dothelial growth factor. J Biol Chem 1991;266:11947-11954.
22. Finkenzeller G, Sparacio A, Technau A, Marmé D, Siemeister G: Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997;15:669-676. (Pubitemid 27389929)
23. TillerayV, Constantinou C, Clemens MJ: Regulation of protein synthesis by in-ducible wild-type p53 in human lung carcinoma cells. FEBS Lett 2006;580:1766-1770.
24. Kaeser MD, Iggo RD: Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002;99:95-100. (Pubitemid 34060322)
25. Cohen PA, Hupp TR, Lane DP, Daniels DA: Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein. FEBS Lett 1999;463,179-184. (Pubitemid 30001743)
26. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 2002;359:845-848.
27. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844. (Pubitemid 23132159)
28. Coultas L, Chawengsaksophak K, Rossant J: Endothelial cells and VEGF in vascular development. Nature 2005;438:937-945. (Pubitemid 43093959)
29. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE: Wild-type p53 suppresses angiogenesis in human leio-myosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-3661. (Pubitemid 30482190)
30. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM: Stabilization of wild-type p53 by hy-poxia-inducible factor 1. Nature 1998;392:405-408.
31. Qin G, Kishore R, Dolan CM, Silver M, Wecker A, Luedemann CN, Thorne T, Hanley A, Curry C, Heyd L, Dinesh D, Kearney M, Martelli F, Murayama T, Goukassian DA, Zhu Y, Losordo DW: Cell cycle regulator E2F1 modulates an-giogenesis via p53-dependent transcrip-tional control of VEGF. Proc Natl Acad Sci USA 2006;103:11015-11020. (Pubitemid 44148410)
32. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman Y, Pinsky DJ, Stern DM: Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355-1361. (Pubitemid 32001019)
33. Szabo S, Deng X, Khomenko T, Chen L, Tolstanova G, Osapay K, Sandor Z, Xiong X: New molecular mechanisms of duodenal ulceration. Ann N Y Acad Sci 2007;1113:238-255. (Pubitemid 350015027)
34. Goldhar AS, Vonderhaar BK, Trott J F, Hovey RC: Prolactin-induced expression of vascular endothelial growth factor via Egr-1. Mol Cell Endocrinol 2005;232:9-19. (Pubitemid 40292935)
35. Schäfer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Höcker M: Oxidative Stress Regulates Vascular En-dothelial Growth Factor-A Gene Transcription through Sp1- and Sp3-depend-ent Activation of Two Proximal GC-rich Promoter Elements. J Biol Chem 2003;278:8190-8198. (Pubitemid 36800562)
36. Tanaka T, Kanai H, Sekiguchi K., Aihara Y, Yokoyama T, Arai M, Kanda T, Nagai R, Kurabayashi M: Induction of VEGF Gene Transcription by IL-1 â is Mediated Through Stress-activated MAP Kinases and Sp1 Sites in Cardiac Myocytes. J Mol Cell Cardiol 2000;32:1955-1967.
37. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-28228. (Pubitemid 26374633)
38. Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ: Physical interaction between p53 and primary response gene Egr-1. Int J Oncol 2001;18,863-870.
39. Salimath B, Marmé D, Finkenzeller G: Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 2000;19:3470-3476. (Pubitemid 30487444)
40. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM: TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010;106:1061-1071.
41. Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P: Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993;12:3879-3891. (Pubitemid 23282764)
42. Taheri F, Bazan HE: Platelet-activating factor overturns the transcriptional repressor disposition of Sp1 in the expression of MMP-9 in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48:1931-1941. (Pubitemid 351261257)
43. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski MR, Bosia A, Albini A,Camussi G: Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Investig 1995;96:940-952.
44. Pitton C, Lanson M, Besson P, Fetissoff F, Lansac J, Benveniste J, Bougnoux P: Presence of PAF-acether in human breast carcinoma: relation to axillary lymph node metastasis. J Natl Cancer Inst 1989;81:1298-1302. (Pubitemid 19221790)
45. Montrucchio G, Sapino A, Bussolati B, Ghisolfi G, Rizea-Savu S, Silvestro L, Lupia E, Camussi G: Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 1989;153:1589-1596.
46. Dvorak HF, Detmar M, Claffey KP, Nagy JA, Van de Water L, Senger DR: Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233-235.